Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Would you recommend SGLT2 inhibitors for patients with sickle cell nephropathy and severely increased albuminuria despite the potential medication associated risk for vaso-occlusive crises?
Related Questions
Do you prioritize adding a GLP-1 receptor agonist over an SGLT-2 inhibitor in patients with CKD related to type 2 diabetes, uncontrolled proteinuria despite being on an ACEi, and obesity?
Under what circumstances would you obtain MR imaging of the kidneys in a patient with ADPKD who was recently diagnosed following CT imaging?
Do you advise your patients with CKD to consume a set amount of fluids daily in an attempt to prevent disease progression?
How do you tailor protein intake recommendations for older patients with stages 3-5 non-dialysis dependent CKD, considering the unique metabolic and physiologic factors that influence protein metabolism in this population?
What is your approach to managing hyperkalemia in pregnant patients with chronic kidney disease?
What is your preferred potassium binder for patients with CKD and hyperkalemia that persists despite dietary potassium restriction?
What is your approach to bisphosphonate use in patients with advanced chronic kidney disease and osteoporosis?
At what serum bicarbonate level do you initiate alkali therapy for patients with chronic kidney disease?
Do you obtain a urinalysis for glucose testing for your patients on SGLT2 inhibitors to assess for medication adherence?
Do you prefer to simultaneously start an ACEi/ARB and SGLT2i or initiate one prior to the other in a patient with proteinuria secondary to diabetic kidney disease?
